Novocure to Report First Quarter 2024 Financial Results
April 01 2024 - 7:00AM
Business Wire
Novocure (NASDAQ: NVCR) announced today that it will report
financial results for the first quarter 2024 on Thursday, May 2,
2024, before the U.S. financial markets open. Novocure management
will host a conference call and webcast to discuss the company’s
financial results for the three months ended March 31, 2024, at
8:00 a.m. EDT on Thursday, May 2, 2024. To access the conference
call by phone, use the following conference call registration link
and dial-in details will be provided. To access the webcast, use
the following webcast registration link.
The slides presented during the webcast and the corporate
presentation can be accessed live from the Investor Relations page
of Novocure’s website, www.novocure.com/investor-relations, and
will be available for at least 14 days following the call. Novocure
has used, and intends to continue to use, its investor relations
website as a means of disclosing material non-public information
and for complying with its disclosure obligations under Regulation
FD.
About Novocure Novocure is a global oncology company
working to extend survival in some of the most aggressive forms of
cancer through the development and commercialization of its
innovative therapy, Tumor Treating Fields. Novocure’s
commercialized products are approved in certain countries for the
treatment of adult patients with glioblastoma, malignant pleural
mesothelioma and pleural mesothelioma. Novocure has ongoing or
completed clinical studies investigating Tumor Treating Fields in
brain metastases, gastric cancer, glioblastoma, liver cancer,
non-small cell lung cancer, pancreatic cancer and ovarian
cancer.
Headquartered in Root, Switzerland and with a growing global
footprint, Novocure has regional operating centers in Portsmouth,
New Hampshire and Tokyo, as well as a research center in Haifa,
Israel. For additional information about the company, please visit
Novocure.com and follow @Novocure on LinkedIn and Twitter.
Forward-Looking Statements In addition to historical
facts or statements of current condition, this press release may
contain forward-looking statements. Forward-looking statements
provide Novocure’s current expectations or forecasts of future
events. These may include statements regarding anticipated
scientific progress on its research programs, clinical study
progress, development of potential products, interpretation of
clinical results, prospects for regulatory approval, manufacturing
development and capabilities, market prospects for its products,
coverage, collections from third-party payers and other statements
regarding matters that are not historical facts. You may identify
some of these forward-looking statements by the use of words in the
statements such as “could” “anticipate,” “estimate,” “expect,”
“project,” “intend,” “plan,” “believe” or other words and terms of
similar meaning. Novocure’s performance and financial results could
differ materially from those reflected in these forward-looking
statements due to general financial, economic, environmental,
regulatory and political conditions and other more specific risks
and uncertainties facing Novocure such as those set forth in its
Annual Report on Form 10-K filed on February 22, 2024, and
subsequent filings with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240401722130/en/
Investors: Ingrid Goldberg investorinfo@novocure.com
media@novocure.com 610-723-7427
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024